BVNKF:OTC-Bavarian Nordic A/S (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 32.64

Change

-2.13 (-6.13)%

Market Cap

N/A

Volume

1.70K

Analyst Target

USD 62.19
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
UCBJY UCB SA ADR

+0.63 (+0.69%)

USD 34.60B
UCBJF UCB SA

N/A

USD 34.60B
ARGNF argenx SE

N/A

USD 31.72B
GNMSF Genmab A/S

-1.52 (-0.64%)

USD 15.44B
IVBIY IVBIY

N/A

USD 9.33B
ZLDPF Zealand Pharma A/S

N/A

USD 8.69B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 8.66B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 8.66B
WXIBF WuXi Biologics

N/A

USD 8.63B
WXXWY WuXi Biologics (Cayman) Inc

N/A

USD 8.44B

ETFs Containing BVNKF

BIOT:SW L&G Pharma Breakthrough U.. 2.69 % 0.00 %

+0.09 (+-0.11%)

N/A
XNZN:XETRA Xtrackers Nordic Net Zero.. 1.84 % 0.00 %

-0.04 (-0.11%)

USD 0.21B
VIDI Vident International Equi.. 0.63 % 0.63 %

+0.25 (+-0.11%)

USD 0.37B
GWX SPDR® S&P International .. 0.00 % 0.40 %

+0.16 (+-0.11%)

N/A
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

+0.02 (+-0.11%)

N/A
EL4D:XETRA Deka STOXX Europe Strong .. 0.00 % 0.00 %

+0.45 (+-0.11%)

USD 0.03B
EL4E:XETRA Deka STOXX Europe Strong .. 0.00 % 0.00 %

+0.17 (+-0.11%)

USD 0.04B
ETLI:XETRA L&G Pharma Breakthrough U.. 0.00 % 0.00 %

+0.07 (+-0.11%)

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 24.44% 73% C 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.44% 73% C 73% C
Trailing 12 Months  
Capital Gain 51.25% 82% B 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 51.25% 82% B 82% B
Trailing 5 Years  
Capital Gain 29.27% 78% C+ 72% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.27% 78% C+ 69% C-
Average Annual (5 Year Horizon)  
Capital Gain 8.66% N/A N/A 52% F
Dividend Return 8.66% N/A N/A 49% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 50.78% N/A N/A 50% F
Risk Adjusted Return 17.06% N/A N/A 51% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:

There is nothing we particularly dislike